test
TO THE EDITORS
We applaud the research performed by David Mosen and colleagues, which suggests improvements in identifying persistent asthmatics when reporting Health Plan Employer Data and Information Set (HEDIS) data.1 We were pleased that the Kaiser Permanente Health Care Program had solicited our input into the research design, so it would help resolve questions about the specificity of the HEDIS asthma measure. The analysis determined that extending the eligibility criteria to 2 years would strengthen the specificity of the current HEDIS measure by improving administrative case identification of true persistent asthmatics.
The authors' recommendation to increase the eligibility from 1 year of identification to 2 years has already been included in the latest measure specifications, which were published last July.2 This is a good example of accelerating the transfer of research into practice, and we encourage this sort of collaboration to ensure that HEDIS remains a robust and valid set of measures for performance measurement.
Phil Renner, AVP
Kevin Weiss, MD
Min Gayles Kim, MPH
National Committee for Quality Assurance Washington, DC
1. Mosen DM, Macy E, Schatz M, et al. How well do the HEDIS asthma inclusion criteria identify persistent asthma? Am J Manag Care. 2005;11:650-654.
2. National Committee for Quality Assurance. Technical Specifications. Washington, DC: National Committee for Quality Assurance; 2005;460. HEDIS 2006. Health Plan Employer Data & Information Set; vol. 2.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More